LifeMap Solutions and Mount Sinai Launch Patient Services App — MountSinaiNY — for Android Devices
First Android app from mHealth pioneer LifeMap Solutions makes mobile patient services portal available to leading healthcare system
NEW YORK – November 15, 2016 – LifeMap Solutions, a subsidiary of BioTime, Inc. (NYSE: BTX), and Mount Sinai Health System today announced that MountSinaiNY is now available for Android devices. This marks LifeMap’s entry into the large and critical Android market, after working with world-class medical and research institutions to build successful iOS apps for the ResearchKit platform. Originally launched on iOS in June, MountSinaiNY offers patients a mobile portal to find centralized information and services, providing greater access to and utilization of the Mount Sinai Health System’s services.
“With MountSinaiNY, we’ve brought our expertise in building user-friendly apps to the Android platform to reach a larger patient population,” said Corey Bridges, CEO of LifeMap Solutions. “Reaching diverse populations is a key promise of the mHealth revolution, and we’re proud to play a role in making that a reality. Expanding into the Android market will improve the quality of large-scale research studies and the impact of clinical care apps.”
MountSinaiNY was developed by Mount Sinai’s Department of Information Technology and LifeMap Solutions. The app offers users a variety of features, including general facility information, appointment booking, bill pay, and access to patient medical records. Future updates to the app will include telemedicine capabilities, wayfinding, and enhanced access to Mount Sinai services.
“Offering MountSinaiNY on Android devices allows more patients to seamlessly access their health information, communicate with their physician, and schedule appointments,” said Bruce Darrow, MD, PhD, Chief Medical Information Officer, Mount Sinai Health System. “This launch is the next step in helping our patients leverage the power of their mobile devices to improve their care.”
Mount Sinai and LifeMap Solutions worked together previously to launch Asthma Health–one of the first apps built using Apple’s ResearchKit platform–and COPD Navigator. This is the first app co-developed by Mount Sinai and LifeMap Solutions to be launched on Android.
About LifeMap Solutions, Inc.
LifeMap Solutions develops innovative digital health solutions by integrating health and wellness information with care team guidance into a secure mHealth platform to deliver digital health solutions that empower patients to make better choices to achieve optimal health outcomes. LifeMap Solutions is a subsidiary of BioTime, Inc., and is headquartered in San Jose, California. For more information, please visit www.lifemap-solutions.com.
BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent stem cell assets. The foundation of our core therapeutic technology platform is pluripotent stem cells that are capable of becoming any of the cell types in the human body. Pluripotent stem cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent stem cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime’s Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.
The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is in the “Honor Roll” of best hospitals in America, ranked No. 15 nationally in the 2016-2017 “Best Hospitals” issue of U.S. News & World Report. The Mount Sinai Hospital is also ranked as one of the nation’s top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s, and Mount Sinai West are ranked regionally. Mount Sinai’s Kravis Children’s Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in “Best Children’s Hospitals.”